Form 4: Bionano Genomics CMO Equity Tax Withholding

Chief Medical Officer Alka Chaubey reported the withholding of 24 shares to satisfy tax obligations related to RSU vesting.

Summary

• Alka Chaubey, Chief Medical Officer of Bionano Genomics, Inc. (BNGO), had 24 shares of common stock withheld by the company.
• The transaction occurred on June 3, 2026, at a price of $1.30 per share.
• The withholding was executed to satisfy tax obligations resulting from the vesting of Restricted Stock Units (RSUs) granted on June 3, 2024.
• Following this transaction, the reporting person holds 620 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard administrative tax withholding process rather than a market-driven trade.

Positives

• The transaction is a routine administrative action related to tax withholding upon RSU vesting, indicating no discretionary sale of shares by the executive.

Negatives

• The transaction reflects a minor reduction in the reporting person's total share ownership.

Risks

• None identified; this is a standard regulatory filing for tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of equity compensation management, common among publicly traded biotechnology firms, and does not signal a change in corporate strategy or executive sentiment.

Comparison to Industry Standards

• The practice of withholding shares to satisfy tax obligations upon RSU vesting is a standard industry practice for U.S. public companies to ensure compliance with tax regulations.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related adjustment.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Trading, Tax Withholding, Equity Compensation